BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion

BeOne Medicines reported Q3 2026 earnings, highlighting Brukinsa's U.S. sales exceeding $1 billion. Management discussed competitive threats, R&D investments, and clinical trial updates. Operating margins are expected to expand by over 10% in 2026, with future growth balanced against investment. The company is expanding its CDK4 inhibitor Phase III study and partnering with Revolution Medicines on precision oncology initiatives.

Original reporting

finance.yahoo.com

Published Nov 5, 2026, 11:19 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 11:28 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · finance.yahoo.com

Decision brief

The 30-second read

$ONCBullishMed

Why it matters

The guidance and trial updates provide fresh material that can move the stock, especially in a sector sensitive to clinical data.

Market read

New guidance and trial expansions are likely to drive short‑term price action for ONC and may influence related oncology biotech stocks.

What to watch

Potential competition from pirtobrutinib and regulatory timelines could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

BeOne Medicines (ONC) held its Q3 2026 earnings call, discussing margin expansion, trial up‑sizes, and partnership with Revolution Medicines.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ONCBullishHigh confidence

Context

BeOne Medicines provided fresh 2026 operating margin guidance (+10% expansion) and updated clinical trial details during its Q3 earnings call.

Expected impact

likely upward pressure as the market prices in stronger margin outlook and pipeline progress

Evidence & confidence

Guidance is a primary disclosure with material numbers; biotech investors react strongly to margin and trial updates.

Market effects

Sector

Positive margin guidance may lift peer BTK inhibitor and broader oncology biotech stocks.

Regional

US biotech sector could see modest gains in pre‑market trading.

Global

Limited to investors tracking oncology pipeline developments.

Counterpoint

What could challenge this read

If trial data fails to meet expectations, the guidance could be revised downward, pressuring the stock.

Key entities

Company
BeOne Medicines Ltd
US‑listed biotech providing BTK inhibitor therapies.
Company
Revolution Medicines
Partner in RAS(ON) inhibitor trials.

Read at source ← All news

$ONCMedAI 8/10

BeOne Medicines Q3 Earnings Call Highlights

BeOne Medicines reported Q3 revenue growth: China +21% ($527M), Europe +41% ($234M), and rest of world +58% ($80M). Management warned of potential revenue pressure for XGEVA and KYPROLIS post-2026 due to competition. The company's CaDAnCe-101 study met primary endpoints, and it plans to expand trials for tacabrutideg. BeOne also advanced solid tumor programs, including BGB-B2033 and BGB-58067, with promising early data.

finance.yahoo.comNov 6

$ONCMed

Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics

BeOne Medicines Ltd. (ONC) reported Q3 revenues of $1.86 billion, exceeding estimates by $120 million. Key products like BRUKINSA and XGEVA saw significant year-over-year growth, while KYPROLIS revenue declined. Other revenue also surpassed expectations.

finance.yahoo.comNov 5

$ONCHighAI 8/10

Jefferies raises BeOne Medicines stock price target on solid quarter

Jefferies raised its price target for BeOne Medicines (ONC) to $470 from $410, citing strong quarterly results and raised guidance. The stock trades near its 52-week high at $387.27. The company reported $1.7B in Q2 2026 revenue, up 29% YoY, and raised its full-year 2026 revenue guidance to $6.6B-$6.8B. Analysts highlight robust margins, revenue growth, and a solid pipeline.

investing.comNov 5

$ONCHigh

BeOne Medicines DRC earnings beat by $2.66, revenue topped estimates

BeOne Medicines DRC (ONC) reported Q3 EPS of $4.55, exceeding estimates by $2.66, with revenue of $1.89B, topping expectations of $1.75B. The stock is up 8.47% over 3 months and 19.10% over 12 months. InvestingPro rates its financial health as 'great performance'.

investing.comNov 5

$ONCHighAI 8/10

BeOne Medicines Q3 Revenue Rises 34% to $1.9 Billion; Raises 2026 Outlook

BeOne Medicines reported Q3 2026 revenue of $1.89 billion, up 34% YoY, with GAAP earnings of $3.28 per ADS. The company raised its full-year revenue guidance to $6.9B-$7.0B. Key products BRUKINSA and TEVIMBRA saw regulatory progress, and the company announced new collaborations and partnerships.

tradingview.comNov 5

$ONCHighAI 9/10

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,

SEC EDGAR 8-KNov 5